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Abstract 
Analysis of the human repertoire of the FK506-binding protein family of peptidyl-
prolyl cis/trans isomerases (FKBPs) has identified an expansion of genes that code for 
human FKBPs in the secretory pathway. There are distinct differences in tissue 
distribution and expression levels of each variant. We describe here the 
characterisation of human FKBP19 (Entrez Gene ID: FKBP11), an FK506-binding 
protein predominantly expressed in vertebrate secretory tissues. The FKBP19 
sequence comprises a cleavable N-terminal signal sequence followed by a putative 
peptidyl-prolyl cis/trans isomerase domain with homology to FKBP12. This domain 
binds FK506 weakly in vitro. FKBP19 mRNA is abundant in human pancreas and 
other secretory tissues and high levels of FKBP19 protein are detected in the acinar 
cells of mouse pancreas. 
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Introduction 
The synthesis, folding and assembly of proteins involves some of the most essential 
and conserved mechanisms of life (Pahl et al., 1997). In eukaryotic systems, several 
families of chaperones and foldases have evolved to catalyse these processes (Fedorov 
and Baldwin, 1997).  The folding of proline-containing polypeptides is catalysed by 
peptidyl-prolyl cis/trans isomerases (PPIases: Fischer et al., 1984). 
 
The PPIase families are classified by sequence homology and pharmacologically by 
their ability to bind the immunosuppressant compounds cyclosporin, FK506 and 
rapamycin, and are otherwise known as immunophilins (reviewed in Galat and 
Riviere, 1998, Galat, 2003). The FK506-binding protein (FKBP) family share a high 
degree of sequence and structural homology and PPIase activity that is specifically 
inhibited by FK506 or rapamycin (Kay, 1996). Since the discovery of the first FKBP 
(Siekierka et al., 1989), several members of this family have been characterised in 
humans and other organisms (Patterson et al., 2002, Galat, 2003). Each member of the 
FKBP family contains one or more PPIase domain, which shows high sequence 
homology with the most abundant member, FKBP12.  
 
Analysis of the genomes of eukaryotic model organisms shows correlations between 
genome size and the number of genes coding for FKBPs, with 4 members present in 
Saccharomyces cerevisiae, 7 in Drosophila melanogaster, and 9 in Caenorhabditis 
elegans (Kay, 2000). In general, eukaryotic organisms appear to have one or two 
FKBPs for every 2,000 genes in their genome. If this pattern applied to the human 
genome, containing around 30,000 genes (Pennisi, 2003), there could be up to 30 
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FKBP sequences in the human genome. Although many cellular processes involving 
FKBPs may be conserved from lower organisms, and degeneracy involving 
cyclophilins or parvulins as alternative PPIases may significantly reduce this predicted 
number. This report describes a survey of the human genome for FK506-binding 
proteins and the biochemical characterisation of a novel member, FKBP19. 
Methods 
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich Company 
Ltd, Poole, UK. 
Cloning 
IMAGE clones containing FKBP sequences were obtained from Research Genetics 
Inc. (Huntsville, AL, USA). These included IMAGE clone 269896 (accession 
numbers N24885 and N36303), containing the full-length FKBP19 coding sequence, 
clone 323084 (accession number W42674), containing a partial FKBP22 sequence, 
and clones 2518850 and 1857997 (accession numbers AI879695 and AI271550), 
which contained overlapping sequences covering the entire FKBP23 coding sequence. 
The FKBP23 clones shared a common internal StuI site. A BamHI-StuI fragment of 
the IMAGE clone 2518850 insert, and a StuI-NotI fragment of clone 1857997 were 
generated. A three-way ligation of these two fragments with a BamHI-NotI digested 
pET21a expression vector produced a full-length human FKBP23 clone. 
Northern Blotting 
Probes were generated to the open reading frames of each FKBP variant shown by 
PCR and radiolabelled with α-32P dCTP using a Megaprime labelling kit (Amersham 
Pharmacia Biotech Ltd. Little Chalfont, UK). These were then used to probe a Human 
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Multiple Tissue Northern and Human RNA Master Blot (Clontech) using ExpressHyb 
(Clontech), according to the recommended protocols. Washed blots were exposed to a 
phosphorimager screen (Molecular Dynamics, Sunnyvale, CA). 
In vitro transcription/translation of hFKBP19 
A full-length FKBP19 expression construct was generated by PCR using primers 
FKBP19/3 and FKBP19/4 (see figure 3) and the resulting product subcloned into 
pET21a using restriction sites incorporated into the primer sequences. The construct 
was then used as a template in the TNT-T7 Quick Coupled Transcription/Translation 
System (Promega UK Ltd, Southampton, UK). Translation products were 
radiolabelled with 35S-methionine (Amersham Pharmacia Biotech Ltd. Little Chalfont, 
UK). Post-translational peptide cleavage was obtained by carrying out the coupled 
reaction in the presence of Canine Pancreatic Microsomal Membranes (Promega). 
Expression constructs 
Full-length expression constructs of FKBP19 and FKBP23 produced insoluble 
material in E.coli, so PCR primers (Genosys Biotechnologies Ltd, Cambridge, UK) 
were designed to amplify regions coding for the PPIase domain of human FKBP19 ( 
GAGGCTGGGCTCGAAACCG andGCCCTTCACCAGCTTTAGCC) and the 
“mature” FKBP23 (complete ORF minus the first 24 amino acids, using primers 5’-
CCCATATGAGACAAAAGAAAGAGGAGAGC-3’ and 5’-
CCCTCGAGTAGTTCATCGTGTTGGTATAC-3’). An in-frame start codon was 
incorporated, where necessary, into PCR primers, as part of an NdeI site, and an XhoI 
site was incorporated at the 3’ end, replacing the native stop codon. The resulting PCR 
fragment was cloned into pET21a (Novagen, Madison, WI, USA), such that the FKBP 
coding sequences were in-frame with a C-terminal His-tag sequence. A similar His-
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Tagged expression construct was generated from the full-length coding region of 
human USA-CYP for use as a negative control for binding studies as previously 
described (Pemberton et al., 2003). An FKBP13 expression construct was made for 
use as a positive control by amplifying a human FKBP13 fragment coding for the 
“mature”, soluble form of the protein (i.e. the full-length minus the first 21 amino 
acids) with primers 5’-CCGAATTCACGGGGGCCGAGGGCAAAAGG-3’ and 5’-
CCAAGCTTCAGCTCAGTTCGTCGCTCTAT-3’. The fragment was subcloned into 
pET21a using the EcoRI and HindIII sites incorporated into the primer sequences. 
Expression and purification of human PPIases 
BL21(DE3) cells (Novagen) transformed with each expression construct were grown 
in flasks, shaking at 200 rpm, at 37°C in 2YT broth supplemented with 50 µg/ml 
ampicillin, 1% glucose. Expression was induced at an OD600 of 0.8 with 1mM IPTG. 
Cells were harvested 2.5 hours after induction. Inclusion body preps were made from 
FKBP19-expressing E.coli as follows: 1g of cells were lysed by sonication in 10 ml 
50 mM sodium phosphate (pH 7.0), 300 mM NaCl, 0.5 mM PMSF, and centrifuged at 
1000g, 15 minutes, to pellet inclusion bodies. These were washed twice in lysis buffer 
and resuspended in lysis buffer containing 6 M guanidine-HCl. After 4 hours mixing 
at 4º, the samples were centrifuged again, and the supernatant was added to 1 ml 
TALON resin (Clontech, Basingstoke, UK). After mixing at 4ºC for 1 hour, the resin 
was collected by centrifugation, (1000 g, 5 minutes), washed twice in 10 ml lysis 
buffer containing 6 M guanidine-HCl and 3 times in guanidine-free lysis buffer. 
Purified FKBP19 was eluted in 1ml fractions with lysis buffer containing 150 mM 
Imidazole. 
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His-tagged FKBP23 was purified as described above, with the exception that the 
protein was purified from the soluble fraction of the cell lysate, and no guanidine-HCl 
was used at any stage. FKBP13 was purified on SP Sepharose resin in 50 mM Bis-Tris 
Propane buffer at pH 9 with a 0-1 M NaCl gradient. Fractions giving the correct size 
band were dialysed into 50 mM Tris, 200 mM NaCl, pH 7.4. Human USA-CYP was 
purified as described (Pemberton et al., 2003). 
Antibodies and Western Blotting 
Protein products and in vitro translation products were separated by SDS-PAGE using 
precast 4-20% Tris-Glycine gels (Invitrogen) and transferred to PVDF membrane 
(Invitrogen). Blots were blocked in 5% dried milk for 1hr, incubated with primary 
antibody/1% milk in PBS for 2hrs, washed in PBS/0.1% Tween-20 three times, 
incubated in secondary antibody/1% milk for 1hr and washed 5 times in PBS/0.1% 
Tween-20. Blots were developed using BCIP/NBT liquid substrate system (Sigma). 
 
For analysis of tagged protein expression in in vitro translation products and E.coli 
extracts, an alkaline phosphatase-conjugated monoclonal anti-T7 antibody was used 
(Novagen) and incubation with secondary antibody was not necessary. For analysis of 
native protein expression in bovine and mouse extracts, a rabbit polyclonal antibody 
was generated to the full-length tagged protein product by Cambridge Research 
Biochemicals. The specificity of this antibody was further improved by purifying 
PPIase-domain-binding species in the immunised rabbit serum using a Hi-Trap NHS-
activated column (Amersham) containing conjugated FKBP19 PPIase domain. An 
alkaline phosphatase-conjugated anti-rabbit IgG antibody was used as a secondary 
antibody. 
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3H-FK506-Binding Assay 
The FK506-binding assay (Siekierka et al., 1990) was carried out in individual 1ml 
columns prepacked with LH20 medium (Amersham Pharmacia Biotech Ltd. Little 
Chalfont, UK) and equilibrated in assay buffer (50 mM Tris-HCl, pH 7.4, 200 mM 
NaCl). 1 µM FKBP was incubated with 12 nM 3H-dihydro-FK506 (NEN Life Science 
Products, Hounslow, UK) for 25 minutes at room temperature before being applied to 
the column. 100 µl fractions were eluted in assay buffer and counted for 10 minutes in 
a Beckman LS 6000IC scintillation counter. 
Immunohistochemistry 
Adult C3H mouse pancreas was fixed in 10% buffered formaldehyde and embedded 
in paraffin wax. 5um thick sections were obtained and de-paraffinised in xylene 
substitute and graded ethanol solutions. Endogenous peroxidase activity was 
quenched with 3% hydrogen peroxide in isopropanol.  
For FKBP19 labelling the sections were microwaved in 10mM citrate buffer (pH 6.0) 
and rinsed with phosphate-buffered saline at room temperature. To inhibit the non-
specific endogenous biotin staining the DAKO Blocking System was used. A blocking 
solution of 10% swine serum (DAKOCytomation) was used for 10 minutes. 
Polyclonal anti-FKBP19 was used at a dilution of 1:100 for one hour at room 
temperature. Biotinylated swine anti rabbit antibody (DAKOCytomation) and 
ChemMate Detection Kit (DAKOCytomation) were used to develop the specific 
signals. The negative control specimen was incubated in swine serum and processed 
identically. 
For insulin labelling the sections were rinsed with phosphate-buffered saline, blocked 
with 10% rabbit serum and incubated with polyclonal guinea pig anti-insulin 
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(DAKOCytomation) at a dilution of 1:500 for one hour at room temperature. 
Peroxidase-conjugated rabbit anti guinea pig (DAKOCytomation) and 
diaminobenzidine (DAKOCytomation) were used to develop the signals. The negative 
control specimen was incubated in rabbit serum and processed identically. All slides 
were counterstained with haemotoxylin. 
Results 
Fifteen FKBP sequences have been identified in the human genome (table 1). Only 
genes where EST-derived sequences are available are included here. Reference to 
hFKBP-12c (described by Galat, 2003) is omitted from these data since no expressed 
sequences corresponding to this predicted sequence were found. The FKBP family can 
be subdivided into four groups by classification of the regions within or surrounding 
the conserved PPIase domains (figure 1). In humans there are multiple subtypes within 
each of these groups. Each subtype may bind different subcellular targets as a result of 
subtle differences in their sequences. The four mammalian FKBP subgroups comprise 
the cytoplasmic, nuclear, TPR-domain, and secretory pathway FKBPs. The 
cytoplasmic FKBPs contain single FKBP domains only (FKBP12 and FKBP12.6: 
(Standaert et al., 1990, Arakawa et al., 1994)). The nuclear FKBPs (FKBP25 and 
FKBP135; (Jin et al., 1992, Ishikawa et al., 1998) contain N-terminal domains of 
unknown function, and one or more nuclear localisation sequences. The TPR-domain 
FKBPs contain two or three FKBP domains and tetratricopeptide repeats (TPRs) 
within the C-terminal FKBP domain (FKBP36, FKBP37, FKBP38, FKBP51 and 
FKBP52; (Meng et al., 1998, Kuzhandaivelu et al., 1996, Lam et al., 1995, Nair et al., 
1997, Peattie et al., 1992).  
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The largest group of human FKBPs are the secretory pathway class of FKBPs (Davis, 
2000), which comprise FKBP13 (Jin et al., 1991), FKBP19 (this article), FKBP22 
(Patterson et al., 2002), two splice variants of FKBP23 (one of which was previously 
identified in mouse: Nakamura et al., 1998), FKBP60 (Shadidy et al., 1999), and 
FKBP65 (Patterson et al., 2002). Members of this group are distinguishable from 
other FKBPs by the presence of N-terminal, leucine-rich, cleavable signal peptides 
and C-terminal endoplasmic reticulum (ER)-retention motifs, which in most cases is a 
variant of the canonical KDEL motif (Munro and Pelham, 1987). Calcium-binding 
EF-hand motifs are also present in the C-terminal region of several of these proteins. 
The PPIase domains of this class of proteins can be identified by the presence of two 
cysteine residues, which are thought to form a disulphide bond in the oxidising 
environment of the ER and stabilise the tertiary structure of the PPIase domain (Jin et 
al., 1991). Other typical features of this group are the presence of two basic amino 
acids 4 residues downstream of the second cysteine residue and a conserved proline 5 
residues thereafter (see figure 2). 
 
FKBP19 (accession number AF238079) represents a previously uncharacterised 
FKBP subtype. The 740bp human FKBP19 cDNA sequence is derived from 6 exons 
on chromosome 12, and contains an open reading frame coding for a 22 kDa protein 
with some unique features. Highly conserved FKBP19 orthologues are present in 
other vertebrates (figure 3) but none have been found in invertebrate species.  
 
A 4kb region of chromosome 12 that lies immediately upstream of FKBP19 was 
found in the Ensembl database and scanned for putative transcription factor binding 
sites using the Biobase MatchTM tool (Goessling et al., 2001). Five putative NKX2-5 
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and four Pax4 binding sites were found in this region, suggesting a role in the 
pancreas (Inoue et al., 1998). Analysis of EST sequences showed that FKBP19 is 
highly expressed in melanocytes and placenta, but is also expressed in pancreatic islet 
cell, senescent fibroblast and breast libraries. A radiolabelled FKBP19 probe showed a 
transcript of ~800bp expressed at high levels in human pancreatic tissue, with low 
expression levels in the other seven tissues probed, and very low levels in brain 
(figure 4, left panel). High levels of expression in the pancreas and other secretory 
tissues such as stomach, pituitary gland, salivary gland and lymph node, were 
confirmed by probing a dotblot containing messenger RNA extracted from 50 
different human tissues (figure 4, right panel). In contrast, FKBP22 and the two 
FKBP23 variants, show low levels of expression in the secretory tissues, being 
expressed at relatively higher levels in the heart. However, differences between the 
expression levels of FKBP22 and the FKBP23s in the brain, for example, show that 
these members of the FKBP family also exhibit tissue-specific expression. 
 
The FKBP domain of FKBP19 sequence demonstrates 38% amino acid identity with 
FKBP12 and 46% with the FK506-binding domain of FKBP13. It contains some of 
the features typical of secretory pathway FKBPs, such as the two cysteine residues, 
and also a conserved basic motif and subsequent proline residue shortly after the 
second cysteine (see figure 2). The FKBP domain of FKBP19 binds FK506 in an in 
vitro binding assay shows binding of FK506 over non-specific binding by a 
structurally-unrelated PPIase USA-CYP (Horowitz et al., 1997). However, FKBP13 
binds over 200 times as much FK506 in the same assay, whereas the binding of 
FK506 by FKBP23 is not detectable over non-specific binding (figure 5). 
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Other features of FKBP19 include a leucine-rich N-terminal leader sequence of 25 
residues, which shows similarities with other known secretory pathway proteins (von 
Heijne, 1983).   Cleavage at the predicted site of  3 kDa would leave a 19 kDa mature 
protein, thus named FKBP19.  The C-terminus of this protein differs from the other 
secretory-pathway FKBPs in that it lacks a calcium-binding EF hand that is typical of 
several other secretory pathway FKBPs and contains a putative transmembrane 
domain (as predicted by PSORT; Nakai and Horton, 1999), followed by a lysine-rich 
C-terminal tail, containing a variant of the di-lysine motif found in ER-membrane 
proteins (Teasdale and Jackson, 1996).  
 
An antibody raised to the PPIase domain of FKBP19 recognised recombinant 
FKBP19, but not the closely related PPIases FKBP12.6 and FKBP23 (figure 6A). 
Affinity chromatography to an FKBP19-conjugated column completely abolished 
detectable antibody binding, showing that the antiserum is specific to FKBP19 (figure 
6B). Anti-FKBP19 detects a doublet of 19-22 kDa in bovine pancreas extracts (fig 
6D). This is likely to be a mixed population of proteins containing cleaved and un-
cleaved N-termini. This is supported by the loss of approximately 3kDa in an in vitro 
reaction in the presence of canine pancreatic microsomes (figure 6E). 
Immunohistochemical analysis of FKBP19 production in the mouse pancreas shows 
high levels of FKBP19 protein, localised throughout the cytoplasmic region of acinar 
cells and concentrated in the perinuclear region of these cells (figures 7A and 7C). 
Low levels are seen in the islets of Langerhans, which were confirmed by 
immunolabelling with an antibody directed to insulin (figure 7D). 
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Discussion 
Analysis of human genome sequence data has confirmed previous reports that there 
are fifteen different FKBP variants expressed in human tissues. It seems likely that 
this number represents the complete human FKBP repertoire, although splice variation 
in those such as FKBP23 may increase the number of different functional FKBPs.  
The conserved sequences of the PPIases suggest that their cellular targets may 
overlap. Common partners of TPR-containing PPIases have been demonstrated 
previously (Ratajczak and Carrello, 1996). Tissue-specific expression profiles, such as 
that shown for FKBP19 above, and the separation of multiple subtypes by subcellular 
localisation signals (figure 1) may be sufficient to avoid much of the erroneous 
binding by promiscuous members of this family. However, the overlapping expression 
profiles and subcellular localisation of FKBPs in the secretory pathway suggest that 
regulation of expression and protein sorting is not enough. This raises the question of 
why multiple isoforms are so highly conserved between species, if they are involved 
in degenerate pathways. Alternatively, subtle differences in the primary sequence of a 
protein could lead to dramatic differences in its affinity for a target. This hypothesis is 
supported by the differential binding abilities of three similar secretory-pathway 
FKBPs for the exogenous ligand, FK506. However, a third explanation could be that 
sequence divergence is required for tertiary structure and functionality in a wide range 
of cellular environments. The presence of a disulphide bond in the FKBP domain 
appears to be necessary for all of the human FKBPs in the secretory pathway. 
Extremes in pH, oxidative or ionic strength in tissues such as the pancreas may be 
why specialised molecules are required for functional protein production and transport 
in these tissues. pH-dependent activity has been demonstrated for other PPIases 
(Ranganathan et al., 1997). 
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There appears to be a wider expansion of secretory FKBPs in vertebrates compared to 
other animals. Analysis of genomic models shows that S.cerevisae has only one FKBP 
in the secretory pathway, whereas Schizosaccharomyces pombe has none at all. There 
are two present in the Drosophila genome, and up to 5 in C.elegans (Kay, 2000). This 
report confirms that at least six secretory pathway FKBPs are present in vertebrates: 
FKBP13, FKBP22, FKBP23 (isoforms a and b), FKBP60 and FKBP65 represent 
closely-related variants of the FKBPs in the ER lumen, although FKBP13 lacks the 
calcium-binding region of the other members of this group. These probably have 
similar functions in folding proteins in the bulk flow of the ER of these tissues, as 
previously suggested for FKBP13 (Bush et al., 1994). FKBP19 represents a highly 
conserved unique FK506-binding protein, which so far appears to be unique to 
vertebrate genomes. Unlike FKBP65, FKBP19 does not appear to be developmentally 
regulated, and is expressed at low levels in many fetal and adult tissues.  FKBP19 may 
be bound to the membrane of secretory microsomes and expression appears to be 
elevated in tissues with exocrine properties. Highly tissue-specific PPIases have been 
previously reported: For example the cyclophilin protein ninaA is specifically 
expressed in the photoreceptor cells of Drosophila and is required for the production 
of rhodopsin (Baker et al., 1994). The expression profile of FKBP19 suggests that its 
role may have a unique role in protein secretion. Identification of cellular targets 
would be required to confirm this hypothesis. 
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Table legends 
Table 1:  
Identification of human EST sequences encoding FKBP-domain proteins. FKBPs are 
grouped by subfamily (see results section: C = cytoplasmic, N = nuclear, TPR = TPR-
containing, ER = secretory pathway). Locuslink Ids and chromosomal positions as 
recorded in the NCBI Locuslink database are shown. 
 
Figure legends 
Figure 1: 
Domain structure of the 13 human FKBPs. 
 
Figure 2:  
Clustal alignment of the PPIase domains of the known human FKBPs. FKBPs are 
grouped by class (C = cytoplasmic, N = nuclear, TPR = FKBPs with tetratricopeptide 
repeats, ER = secretory-pathway). Multiple PPIase domains within the same sequence 
are shown in order from the N-terminal domain. Residues interacting with FK506 are 
shown in bold (from the FKBP12 model: Ikeda et al., 1994)). Regions forming the 
alpha helix (α) or beta sheets (β) within the PPIase domain are also shown (Michnick 
et al., 1991). The two cysteine residues found in secretory-pathway FKBPs are 
indicated with arrows, and the nuclear localisation motif of FKBP25 is underlined. 
 
 
 
Figure 3:  
 22
Clustal alignment showing the predicted amino acid sequences derived from putative 
FKBP19 homologue EST sequences (Thompson et al., 1994). Accession numbers as 
follows: Bos taurus (derived from two overlapping ESTs: AV589801 and 
AV615018); Rattus norvegicus: BF555031 and AA875098; Mus musculus: 
NM_024169, Xenopus laevis: BC078481; Dani rerio: AL591389. "*" = identical or 
conserved residues in all sequences in the alignment ":" = indicates conserved 
substitutions "." = indicates semi-conserved substitutions. Amino acids predicted to 
comprise the PPIase domains are in bold. The cysteine residues specific to secretory-
pathway FKBPs are underlined. The predicted N-terminal signal sequences and 
transmembrane regions have dotted underlines. 
 
 
Figure 4:  
(Left) Clontech’s Human Multiple Tissue Northern was probed with a 32P-labelled 
probe generated from the coding sequences of FKBP19, FKBP22 or FKBP23 
Approximate sizes of transcripts are shown on the left. Lanes represent mRNA 
isolated from (1) heart, (2) brain, (3) placenta, (4) lung, (5) liver, (6) skeletal muscle, 
(7) kidney, (8) pancreas. (Right) Results obtained by using the FKBP19-specific probe 
with a Clontech human mRNA Master Blot, which contains normalised RNA samples 
from 42 different human tissues: A1-8: whole brain, amygdala, caudate nucleus, 
cerebellum, cerebral cortex, frontal lobe, hippocampus, medulla oblongata; B1-7: 
ocipital lobe, putamen, substantia nigra, temporal lobe, thalamus, sub-thalamic 
nucleus, spinal cord; C1-8: heart, aorta, skeletal muscle, colon, bladder, uterus, 
prostate, stomach; D1-8: testis, ovary, pancreas, pituitary gland, adrenal gland, thyroid 
gland, salivary gland, mammary gland; E1-8: kidney, liver, small intestine, spleen , 
 23
thymus, peripheral leukocyte, lymph node, bone marrow; F1-4: appendix, lung, 
trachea, placenta; G1-7: fetal brain, fetal heart, fetal kidney, fetal liver, fetal spleen, 
fetal thymus, fetal lung; H7-8: human gDNA 100 ng, human gDNA 500 ng. 
 
Figure 5:  
FK506-binding by FKBP13 (left panel), FKBP19 or FKBP23 (right panel). 1 µM 
protein was preincubated with 12 nM 3H-dihydro-FK506 before bound compound was 
separated from unbound on a 1.8ml LH20 column. 100µl fractions were assayed by 
liquid scintillation. 
 
Figure 6:   
Western blot showing the specificity of anti-FKBP19 antiserum. Each lane contains 
equivalent loadings (0.4g) of protein from the following: (1) lysate from IPTG-
induced E.coli containing an expression construct for His-tagged FKBP19 PPIase 
domain (see methods); (2) purified recombinant FKBP12.6 (3) semi-purified 
recombinant FKBP23. Panel A shows a blot probed with anti-FKBP19 after elution 
from a solid-phase “blank” affinity column; (B) Western blot probed with serum 
eluted from an FKBP19-conjugated column (see methods); (C) Coomassie stained gel 
of the same samples. (D) Bovine pancreas extract probed with anti-FKBP19. (E) 
Western blot of an in vitro FKBP19 translation product carried out in the absence (-) 
or presence (+) of canine pancreatic microsomes (see methods).  
 
Figure 7: 
Immunohistochemical localisation of FKBP19 in mouse pancreas sections. (A) 
Pancreas section incubated with affinity-purified anti-FKBP19 (20x) showing 
 24
labelling of the exocrine tissue; (B) negative control showing staining produced with 
secondary antibody incubation; (C) 60x view of FKBP19 immunostaining; (D) 
adjacent section to that shown in (C) immunolabelled for insulin to show positive 
staining in the beta cells of the islets of Langerhans, and negative staining in the 
exocrine region of the pancreas. 
 
 
 
 
  
 
Table 1:  
FKBP Refseq ID Locuslink Class Chromosome 
FKBP12 FKBP1 2280 C 20p13 
FKBP12.6 FKBP1B 2281 C 2p23 
FKBP25 FKBP3 2287 N 14q21 
FKBP135 KIAA0674 23307 N 9q32 
FKBP36 FKBP6 8468 TPR 7q11 
FKBP37 AIP 9049 TPR 11q13 
FKBP38 FKBP8 23770 TPR 19p12 
FKBP51 FKBP5 2289 TPR 6p21 
FKBP52 FKBP4 2288 TPR 12p13 
FKBP13 FKBP2 2286 ER 11q13 
FKBP19 FKBP11 51303 ER 12q13 
FKBP22 FKBP14 55033 ER 7p15 
FKBP23 FKBP7 51661 ER 2q31 
FKBP60 FKBP9 11328 ER 7p11 
FKBP65 FKBP10 60681 ER 17q21 
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Figure 1: 
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Figure 2: 
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Figure 3: 
 
H.sapiens         MTLRPSLLPLH--LLLLLLLSAAVCRAEAGLETESPVRTLQVETLVEPPEPCAEPAAFGD 58 
B.taurus          MTLRPSLLPLRLLLLLLLLLRGAVCQAEAGSXTESPVRTLQVETLVEPPEPCAEPATFGD 60 
R.norvegicus      MTLRPLLLPLR--LLLLLLISGAVCRAEAEVETESPVRTLQVETLVQPPESCTESAAFGD 58 
M.musculus        MTLSPLLLPLQ--LLLLLLFSGAVCRAEAGPETESPVRTLQVETLVQPPESCTESAAIGD 58 
X.laevis          MLWG---------FVLLLLLSPATLRAETPEEDSENVTELVIET-VEKPDSCTETAVMGD 50 
D.rerio           MATRTG-------IVLIFLAVFAFVAAEDGESKESVIEQLVVETLVMP-ESCTITSEMGD 52 
                  *            ::*::*   *   **     .. :  * :** *   :.*: .: :** 
 
H.sapiens         TLHIHYTGSLVDGRIIDTSLTRDPLVIELGQKQVIPGLEQSLLDMCVGEKRRAIIPSHLA 118 
B.taurus          TLHIHYSGSLVDGRIFDTSLTRDPLVIELGQKQVIPGLEQSLLDMCVGEKRRVIIPSHLA 120 
R.norvegicus      TLHIHYTGSLADGRIIDTSLTRDPLVIELGQKQVIPGLEQSLLDMCVGEKRRAVIPSHLA 118 
M.musculus        TLHIHYTGSMVDGRIIDTSLTRDPLVIELGQKQVIPGLEQSLLDMCVEEKRRAVIPSHLA 118 
X.laevis          TIHLHYTGRLEDGRIIDSSLSRDPLVVELGKKQVIPGLETSLVGMCVGEKRKVVIPPHLA 110 
D.rerio           TLQIHYTGRLMDGKVIDTSLSREPLVVELGKRSVITGLEQALVGVCEGQKIKAMIPAHLA 112 
                  *:::**:* : **:::*:**:*:***:***::.**.*** :*:.:*  :* :.:**.*** 
 
H.sapiens         YGKRGFPPSVPADAVVQYDVELIALIRANYWLKLVKGILPLVGMAMVPALLGLIGYHLYR 178 
B.taurus          YGKRGFPPSIPADAELHFDVELIALIRANYWQKLVKGILPLVGMAMVPALLGLIGYHLYR 180 
R.norvegicus      YGKRGYPPSIPADAVVQYDVELIALIRANYWQKLLKGILPLVGMAMVPALLGLIGYHLYK 178 
M.musculus        YGKRGYPPSIPADAVVQYDVELIALIRANYWQKLLKSILPLVGIAMVPALLGLIGYHLYR 178 
X.laevis          YGKKGYPPSIPGDAVLQFETEVMALFKPTPWQTIVNDVFPLL------HWFGTHAFGAYW 164 
D.rerio           YGKRGYPPTIPGDSTLEFEVEVISLSQQTPWQKLINDILPLLCLALVPTLLGLVGLYLYN 172 
                  ***:*:**::*.*: :.::.*:::* : . * .:::.::**:        :*  .   *  
 
H.sapiens         KANRPKVSKKKLKEEKRNKSKKK 201 
B.taurus          KASSPKISKKKLKEEKRNKSKKK 203 
R.norvegicus      KASTPRVSKKKLKEEKRNKSKKK 201 
M.musculus        KASRPKVSKKKLKEEKPNKSKKK 201 
X.laevis          LSLVLQI---------------- 171 
D.rerio           KAHAQPQGKKKSKDKK---SKKK 19 
  30
 
Figure 4: 
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Figure 5:  
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Figure 7: 
 
 
 
